| Exhibit 99.1 |
Press Release
CONTACT: |
| Tricia Haugeto |
|
| Array BioPharma Inc. |
|
| (303) 386-1193 |
|
| thaugeto@arraybiopharma.com |
ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE
THIRD QUARTER OF FISCAL 2005
Boulder, Colo., (May 9, 2005) - Array BioPharma Inc. (NASDAQ: ARRY) today reported financial results for the third quarter of fiscal 2005, ended March 31, 2005.
For the third quarter of fiscal 2005, Array reported total revenue of $11.6 million, compared to revenue of $9.7 million for the same period in fiscal 2004. Collaboration revenue increased $1.3 million, compared to the same period last year, from new and expanded research collaborations. Net loss was $6.2 million, or ($0.16) per share, for the third quarter, compared to a net loss of $9.7 million, or ($0.34) per share, for the same quarter in fiscal 2004. Array ended the third quarter of fiscal 2005 with $90.5 million in cash and marketable securities.
“We are advancing our product pipeline, focused primarily on treatments for cancer and inflammatory disease, and we are on track to file two INDs in 2005,” said Robert E. Conway, Chief Executive Officer, Array BioPharma. “In addition, we are delighted to have expanded our collaboration with Genentech, further validating our leadership position in small molecule cancer research.”
Recent Accomplishments: | ||
| ||
Advancing Proprietary Research Programs | ||
• |
| Continued progress on the Phase I clinical trial for ARRY-142886 (AZD6244), a novel MEK inhibitor for cancer discovered by Array and out-licensed to AstraZeneca. |
• |
| Advanced regulated preclinical safety testing and formulation studies for ARRY-334543, a potent, orally active, small molecule inhibitor of EGFR and ErbB-2 (dual inhibitor) for use in the treatment of cancer. Presented preclinical data on this compound at the recent American Association for Cancer Research conference. |
• |
| Evaluated select compounds in advanced efficacy and tolerability models from the p38 and MEK inhibitor target classes for inflammation and from the ErbB-2 inhibitor target class for cancer. |
• |
| Continued research on several other proprietary programs that are in early preclinical evaluation, lead optimization and lead generation. |
-more-
Expanding Research Collaborations | ||
• |
| Expanded a collaboration agreement with Genentech, Inc. to develop small molecule drugs against an additional protein target in the field of oncology. The original collaboration, which began in January 2004, was formed to advance two of Array’s proprietary oncology programs into clinical development. Under the expanded agreement, Array will receive additional research funding, as well as research and development milestone payments and product royalties based on the success of the new program. Genentech will have the sole responsibility for clinical development and commercialization of the resulting products. |
Array reported revenue of $33.5 million for the nine-month period ended March 31, 2005, compared to revenue of $24.5 million for the same period in fiscal 2004. Net loss for the nine months ended March 31, 2005, was $16.7 million, or ($0.51) per share, compared to a net loss of $21.9 million, or ($0.77) per share, reported in the same period in fiscal 2004.
Array will hold a conference call on Tuesday, May 10, 2005, at 9:00 a.m. eastern time to discuss these results. If there is any additional information provided during this call, it will be available on a replay of the call and as a web cast on www.arraybiopharma.com. Robert E. Conway, Chief Executive Officer, and Michael Carruthers, Chief Financial Officer, will lead the call.
Conference Call Information | ||
Date: |
| Tuesday, May 10, 2005 |
Time: |
| 9:00 a.m. eastern time |
Toll-Free: |
| (800) 478-6251 |
Toll: |
| (913) 981-5558 |
Pass Code: |
| 4484757 |
Web Cast: |
| www.arraybiopharma.com |
There will be a replay of the conference call for one week, which can be accessed in the United States by dialing toll-free (888) 203-1112, and outside the United States (719) 457-0820. The access code is 4484757. Replay of the call will also be available as a web cast on Array’s web site at www.arraybiopharma.com.
About Array BioPharma:
Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of orally active drugs to address significant unmet medical needs. Our proprietary drug development pipeline is primarily focused on the treatment of cancer and inflammatory disease and includes several small molecule drug candidates that are designed to regulate targets in therapeutically important biologic pathways. In addition, leading pharmaceutical and biotechnology companies access our drug discovery technologies and expertise through collaborations to design, create, optimize and evaluate drug candidates across a broad range of therapeutic areas. For more information on Array, please go to www.arraybiopharma.com.
-more-
Forward-Looking Statement:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties, including those discussed in our annual report filed on form 10-K for the year ended June 30, 2004, and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to achieve and maintain profitability, the extent to which the pharmaceutical and biotechnology industries are willing to in-license drug candidates for their product pipelines and to collaborate with and fund third parties for their drug discovery activities, our ability to out-license our proprietary candidates on favorable terms, our ability to continue to fund and successfully progress internal research efforts and to create effective, commercially viable drugs, risks associated with our dependence on our collaborators for the clinical development and commercialization of our out-licensed drug candidates, the ability of our collaborators and of Array to meet drug objectives, including clinical trials, tied to milestones and royalties, and our ability to attract and retain experienced scientists and management. We are providing this information as of May 9, 2005. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.
-more-
Array BioPharma Inc.
Condensed Statement of Operations
(in thousands, except per share amounts)
|
| Three Months Ended |
| Nine Months Ended |
| ||||||||
|
| March 31, |
| March 31, |
| ||||||||
|
| 2005 |
| 2004 |
| 2005 |
| 2004 |
| ||||
|
| (unaudited) |
| (unaudited) |
| ||||||||
Revenue: |
|
|
|
|
|
|
|
|
| ||||
Collaboration revenue |
| $ | 8,919 |
| $ | 7,667 |
| $ | 25,812 |
| $ | 21,585 |
|
License and milestone revenue |
| 2,637 |
| 2,021 |
| 7,649 |
| 2,893 |
| ||||
Total revenue |
| 11,556 |
| 9,688 |
| 33,461 |
| 24,478 |
| ||||
|
|
|
|
|
|
|
|
|
| ||||
Operating expenses: |
|
|
|
|
|
|
|
|
| ||||
Cost of revenue including related research and development |
| 9,573 |
| 8,480 |
| 27,830 |
| 22,962 |
| ||||
Provision for excess inventory |
| — |
| 5,616 |
| — |
| 5,616 |
| ||||
Research and development for proprietary drug discovery |
| 6,476 |
| 3,511 |
| 16,270 |
| 12,108 |
| ||||
Selling, general and administrative |
| 2,316 |
| 1,912 |
| 6,992 |
| 5,990 |
| ||||
Total operating expenses |
| 18,365 |
| 19,519 |
| 51,092 |
| 46,676 |
| ||||
|
|
|
|
|
|
|
|
|
| ||||
Loss from operations |
| (6,809 | ) | (9,831 | ) | (17,631 | ) | (22,198 | ) | ||||
Interest income |
| 574 |
| 99 |
| 904 |
| 268 |
| ||||
Net loss |
| $ | (6,235 | ) | $ | (9,732 | ) | $ | (16,727 | ) | $ | (21,930 | ) |
|
|
|
|
|
|
|
|
|
| ||||
Basic and diluted net loss per share |
| $ | (0.16 | ) | $ | (0.34 | ) | $ | (0.51 | ) | $ | (0.77 | ) |
|
|
|
|
|
|
|
|
|
| ||||
Number of shares used to compute per share data |
| 38,309 |
| 28,601 |
| 32,599 |
| 28,416 |
| ||||
Summary Balance Sheet Data
(in thousands)
|
| March 31, |
| June 30, |
| ||
|
| 2005 |
| 2004 |
| ||
|
| (unaudited) |
|
|
| ||
Cash, cash equivalents and marketable securities |
| $ | 90,503 |
| $ | 37,446 |
|
Property, plant and equipment, gross |
| 61,764 |
| 57,557 |
| ||
Working capital |
| 75,493 |
| 25,905 |
| ||
Total assets |
| 127,708 |
| 77,764 |
| ||
Stockholders’ equity |
| 106,610 |
| 55,630 |
| ||